A share price of Artiva Biotherapeutics Inc [ARTV] is currently trading at $4.74, up 1.94%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ARTV shares have gain 43.64% over the last week, with a monthly amount glided 39.82%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright started tracking the stock with Buy rating on December 30, 2024, and set its price target to $20. On August 13, 2024, Wedbush initiated with a Outperform rating and assigned a price target of $18 on the stock. TD Cowen started tracking the stock assigning a Buy rating. Needham initiated its recommendation with a Buy and recommended $23 as its price target on August 13, 2024. Jefferies started tracking with a Buy rating for this stock on August 13, 2024, and assigned it a price target of $21. In a note dated August 13, 2024, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $23 on this stock.
Artiva Biotherapeutics Inc experienced fluctuations in its stock price throughout the past year between $1.47 and $11.55. Currently, Wall Street analysts expect the stock to reach $20.5 within the next 12 months. Artiva Biotherapeutics Inc [NASDAQ: ARTV] shares were valued at $4.74 at the most recent close of the market. An investor can expect a potential return of 332.49% based on the average ARTV price forecast.
Analyzing the ARTV fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.49, Equity is -0.46 and Total Capital is -0.63. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.56 points at the first support level, and at 4.38 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.00, and for the 2nd resistance point, it is at 5.26.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Artiva Biotherapeutics Inc [NASDAQ:ARTV] is 11.65. As well, the Quick Ratio is 11.65, while the Cash Ratio is 2.29.
Transactions by insiders
Recent insider trading involved Aslan Fred, President and CEO, that happened on Dec 15 ’25 when 3187.0 shares were sold. Director, FRED ASLAN completed a deal on Dec 15 ’25 to buy 12749.0 shares. Meanwhile, President and CEO Aslan Fred sold 6375.0 shares on Nov 17 ’25.
